Skip to content

Ardelyx ARDX Accrued medical affairs expenses

Accrued medical affairs expenses at other companies

BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$224K
Schering-Plough logo
Schering-PloughSGP
$2.18M+70.2%
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
$58.92M+20.6%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$34.33M+87.9%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$17.65M+13.5%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$29.16M+34.8%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.5B+75.8%
Enterprise value$1.67B+71.5%
P/S3.5×+1.1×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept ardx:AccruedMedicalAffairsExpensesCurrent.

The official record: Ardelyx’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's accrued medical affairs expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's accrued medical affairs expenses?
Ardelyx (ARDX) reported accrued medical affairs expenses of $2.54M in Q4 2025.
What does accrued medical affairs expenses mean?
Accrued liabilities for activities related to medical education, clinical trial support, and engagement with healthcare professionals. These expenses are essential for establishing the clinical profile and scientific credibility of a company's therapeutic products. Tracking these accruals provides insight into the company's investment in medical communication and post-market clinical evidence generation.